Medivir AB (Medivir AB) Operating Income : $-8.67 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Medivir AB Operating Income?

Medivir AB's Operating Income for the three months ended in Dec. 2023 was $-2.15 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.67 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Medivir AB's Operating Income for the three months ended in Dec. 2023 was $-2.15 Mil. Medivir AB's Revenue for the three months ended in Dec. 2023 was $0.43 Mil. Therefore, Medivir AB's Operating Margin % for the quarter that ended in Dec. 2023 was -497.69%.

Good Sign:

Medivir AB operating margin is expanding. Margin expansion is usually a good sign.

Medivir AB's 5-Year average Growth Rate for Operating Margin % was 1.40% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medivir AB's annualized ROC % for the quarter that ended in Dec. 2023 was -61.05%. Medivir AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -580.66%.

Medivir AB Operating Income Historical Data

The historical data trend for Medivir AB's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Operating Income Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-13.63

-6.66

-7.09

-8.54

-9.04

Medivir AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Income	Get a 7-Day Free Trial															-1.91	-1.86	-2.50	-2.17	-2.15

Medivir AB Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.67 Mil.

Medivir AB (OTCPK:MVRBF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medivir AB's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-8.6 * ( 1 - 0% )	/	( (13.451	+	14.724)	/ 2 )
=	-8.6	/	14.0875
=	-61.05 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15.887	-	0	-	( 5.512	-	max(0, 3.581	-	6.017	+	5.512	))
=	13.451

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.068	-	1.595	-	( 16.526	-	max(0, 5.725	-	17.474	+	16.526	))
=	14.724

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Medivir AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.904	/	( ( (1.173 + max(-3.076, 0))	+	(1.205 + max(-5.259, 0)) )	/	2 )
=	-6.904	/	( ( 1.173	+	1.205 )	/	2 )
=	-6.904	/	1.189
=	-580.66 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.505	+	0	+	8.8817841970013E-16)	-	(0	+	0	+	3.581)
=	-3.076

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.245)	-	(1.595	+	0	+	3.909)
=	-5.259

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Medivir AB's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.15	/	0.432
	=	-497.69 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Medivir AB Operating Income Related Terms

Thank you for viewing the detailed overview of Medivir AB's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.